|
US5482931A
(en)
|
1993-06-29 |
1996-01-09 |
Ferring Ab |
Stabilized pharmaceutical peptide compositions
|
|
AT409081B
(de)
|
2000-02-16 |
2002-05-27 |
Gebro Pharma Gmbh |
Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
|
|
EP1188443A1
(en)
|
2000-09-15 |
2002-03-20 |
Ferring BV |
Improved protocol for paracentesis
|
|
DE10114178A1
(de)
|
2001-03-23 |
2002-10-10 |
Aventis Pharma Gmbh |
Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
|
|
US20040153032A1
(en)
*
|
2002-04-23 |
2004-08-05 |
Garribotto John T. |
Dispenser for patient infusion device
|
|
US6991800B2
(en)
|
2002-06-13 |
2006-01-31 |
Vicuron Pharmaceuticals Inc. |
Antifungal parenteral products
|
|
US20040022792A1
(en)
*
|
2002-06-17 |
2004-02-05 |
Ralph Klinke |
Method of stabilizing proteins at low pH
|
|
BRPI0406668A
(pt)
*
|
2003-01-09 |
2005-12-20 |
Baxter Healthcare Sa |
Recipiente de segurança, processo para a produção do mesmo, e, uso de um meio que contém pelo menos um polìmero
|
|
GT200600031A
(es)
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
|
WO2006138181A2
(en)
|
2005-06-14 |
2006-12-28 |
Amgen Inc. |
Self-buffering protein formulations
|
|
DK1984012T3
(en)
|
2006-02-13 |
2016-03-29 |
Ferring Bv |
USE OF peptidic vasopressin receptor agonists
|
|
GB0700523D0
(en)
|
2007-01-11 |
2007-02-21 |
Insense Ltd |
The Stabilisation Of Proteins
|
|
US20100311655A1
(en)
|
2007-06-07 |
2010-12-09 |
Mdrna, Inc. |
Intranasal carbetocin formulations and methods for the treatment of autism
|
|
US7960336B2
(en)
|
2007-08-03 |
2011-06-14 |
Pharmain Corporation |
Composition for long-acting peptide analogs
|
|
US9050286B2
(en)
|
2007-08-14 |
2015-06-09 |
Ferring B.V. |
Use of peptidic vasopression receptor agonists
|
|
US20100311642A1
(en)
|
2007-09-28 |
2010-12-09 |
Ferring B.V. |
Use of v2 receptor antagonists in combination with vaso pressinergic agnosts
|
|
WO2009062174A1
(en)
|
2007-11-08 |
2009-05-14 |
University Of Utah Research Foundation |
Use of angiogenesis antagonists in conditions of abnormal venous proliferation
|
|
KR20210049186A
(ko)
|
2007-11-30 |
2021-05-04 |
애브비 바이오테크놀로지 리미티드 |
단백질 제형 및 이의 제조방법
|
|
US8815232B2
(en)
|
2008-08-26 |
2014-08-26 |
Kyon Biotech Ag |
Compositions and methods for treating cancer
|
|
EP2161030A1
(en)
*
|
2008-09-09 |
2010-03-10 |
Rijksuniversiteit te Groningen |
Oxytocin formulations and uses thereof
|
|
EP2344200A2
(en)
*
|
2008-09-19 |
2011-07-20 |
Nektar Therapeutics |
Modified therapeutics peptides, methods of their preparation and use
|
|
EP2346901A1
(en)
|
2008-10-20 |
2011-07-27 |
Abbott Laboratories |
Antibodies that bind to il-18 and methods of purifying the same
|
|
US20100203014A1
(en)
|
2009-02-04 |
2010-08-12 |
Aegis Therapeutics Llc |
Zwitterionic buffered acidic peptide and protein formulations
|
|
US20100260739A1
(en)
|
2009-03-09 |
2010-10-14 |
Bioatla, Llc |
Mirac Proteins
|
|
EP2440200B8
(en)
|
2009-06-08 |
2014-10-15 |
UCL Business PLC |
Treatment of portal hypertension using l-ornithine phenylacetate
|
|
EP2446552B1
(en)
*
|
2009-06-24 |
2016-08-10 |
Nokia Solutions and Networks Oy |
Relay node and method for changing the timeslot type according to the received information
|
|
US8613892B2
(en)
*
|
2009-06-30 |
2013-12-24 |
Abbott Diabetes Care Inc. |
Analyte meter with a moveable head and methods of using the same
|
|
AU2011279144A1
(en)
|
2010-07-14 |
2013-01-24 |
Cumberland Emerging Technologies, Inc |
Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-A2 receptor antagonists
|
|
JO3400B1
(ar)
|
2010-09-30 |
2019-10-20 |
Ferring Bv |
مركب صيدلاني من كاربيتوسين
|
|
CN102440957B
(zh)
*
|
2011-12-16 |
2013-09-25 |
深圳市健元医药科技有限公司 |
醋酸特利加压素鼻腔喷雾剂及其制备方法
|
|
WO2013106072A1
(en)
|
2012-01-10 |
2013-07-18 |
Sorbent Therapeutics, Inc. |
Compositions comprising crosslinked cation-binding polymers and uses thereof
|
|
JO3109B1
(ar)
|
2012-05-10 |
2017-09-20 |
Ferring Bv |
منبهات لمستقبلات v1a
|
|
CA2891281C
(en)
|
2012-11-12 |
2023-11-28 |
The Regents Of The University Of Colorado, A Body Corporate |
Disease severity index for assessment of chronic liver disease and method for diagnosis of three distinct subtypes of primary sclerosing cholangitis
|
|
AU2014256944B2
(en)
|
2013-04-26 |
2019-06-27 |
La Jolla Pharma, Llc |
Compositions and methods for treating renal failure
|
|
US20150056194A1
(en)
|
2013-08-21 |
2015-02-26 |
Georgia Regents Research Institute, Inc. |
Modified green tea polyphenols and methods thereof for treating liver disease
|
|
US20150328317A1
(en)
|
2014-05-13 |
2015-11-19 |
Eagle Pharmaceuticals, Inc. |
Aqueous buffer-free bivalirudin compositions
|
|
US20200237856A1
(en)
|
2014-10-24 |
2020-07-30 |
Mallinckrodt Hospital Products IP Limited |
Method of treating patients with hepatorenal syndrome type 1
|
|
US20200046798A1
(en)
|
2014-10-24 |
2020-02-13 |
Mallinckrodt Hospital Products IP Limited |
Method of treating patients with hepatorenal syndrome type 1
|
|
CN107206049B
(zh)
|
2014-10-24 |
2021-12-07 |
马林克罗特医疗产品知识产权公司 |
治疗患1型肝肾综合征的患者的方法
|
|
WO2017150824A1
(ko)
|
2016-03-03 |
2017-09-08 |
가천대학교 산학협력단 |
마이크로 니들 및 이의 제조방법
|
|
US20190249173A1
(en)
*
|
2016-05-04 |
2019-08-15 |
Chandra Vargeese |
Methods and compositions of biologically active agents
|
|
GB201721846D0
(en)
|
2017-12-22 |
2018-02-07 |
Arecor Ltd |
Novel composition
|
|
US11318183B2
(en)
*
|
2018-03-20 |
2022-05-03 |
Mankind Pharma Ltd. |
Stable pharmaceutical composition of vasopressin
|
|
MX2020013389A
(es)
|
2018-06-15 |
2021-03-31 |
Ferring Bv |
Composiciones de terlipresina y usos de las mismas.
|
|
CN108659104B
(zh)
*
|
2018-07-03 |
2020-06-09 |
北京市新里程医药科技有限公司 |
一种特利加压素的制备方法及其药物组合物
|
|
CN109010795B
(zh)
*
|
2018-09-12 |
2021-10-22 |
南京康舟医药科技有限公司 |
醋酸特利加压素注射液以及其制备方法
|
|
WO2020128499A1
(en)
*
|
2018-12-21 |
2020-06-25 |
Arecor Limited |
Novel composition
|